SCHEMBL3018692

SCHEMBL3018692

O=S(=O)(c1cccc(Cl)c1)N1CCN(c2nc(Cc3ccc(Cl)cc3)cs2)CC1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
GBA1 P04062 2/20 0.46
PIK3CA P42336 1/20 0.45
MTOR P42345 1/20 0.45
POLB P06746 1/20 0.45
HSD11B1 P28845 1/20 0.45
LMNA P02545 2/20 0.43
TSHR P16473 1/20 0.43
KDM4E B2RXH2 2/20 0.43
PTPN11 Q06124 1/20 0.43
CHRM4 P08173 1/20 0.42
HTT P42858 2/20 0.42
LPAR2 Q9HBW0 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 1/20 0.41
PKM P14618 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017408 0.94 ALDH1A1 (0.51) ALDH1A1MEN1KMT2AGBA1PIK3CA
SCHEMBL3015788 0.93 MEN1 (0.46) ALDH1A1MEN1KMT2AGBA1PIK3CA
SCHEMBL3016050 0.93 ALDH1A1 (0.46) ALDH1A1MEN1KMT2AGBA1PIK3CA
SCHEMBL3002585 0.92 ALDH1A1 (0.46) ALDH1A1MEN1KMT2AGBA1PIK3CA
SCHEMBL3016495 0.92 ALDH1A1 (0.48) ALDH1A1MEN1KMT2AGBA1PIK3CA
SCHEMBL3007842 0.91 MEN1 (0.44) ALDH1A1MEN1KMT2AGBA1PIK3CA
SCHEMBL3005969 0.91 GBA1 (0.44) ALDH1A1MEN1KMT2AGBA1POLB
SCHEMBL3021982 0.91 ALDH1A1 (0.46) ALDH1A1MEN1KMT2AGBA1PIK3CA
SCHEMBL3010490 0.91 POLB (0.44) ALDH1A1MEN1KMT2AGBA1POLB
SCHEMBL3016067 0.91 ALDH1A1 (0.51) ALDH1A1MEN1KMT2AGBA1PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885MEN1 454/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.